 |
| Title |
Endothelin-1 Concentration is Related to Pain Threshold in a Cancer Pain Mouse Model |
| Clinical Question |
Are higher levels of endothelin-1 related to higher levels of pain than lower levels of endothelin-1 in Oral Squamous Cell Carcinoma? |
| Clinical Bottom Line |
ET-1 concentration is a determinant of the level of pain in a cancer pain mouse model. Future treatment regimens for cancer pain directed at ET-1 receptor antagonism (ET receptor A) through customized care shows promise. (See Comments on the CAT below) |
| Best Evidence |
(you may view more info by clicking on the PubMed ID link) |
| PubMed ID |
Author / Year |
Patient Group |
Study type
(level of evidence) |
| #1) 17664075 | Pickering/2007 | Melanoma- 5, OSCC-5, Control-3 | Randomized controlled trial in the mouse | | Key results | The mean percent difference in 50% paw withdrawal threshold for the SCC group was significantly lower than both the melanoma group and the sham group on all post-inoculation testing days. The mean percent difference in 50% paw withdrawal threshold for the melanoma groups was significantly lower than the Sham group on all post-inoculation testing days except for day 4. The correlation between tumor volume and 50% paw withdrawal threshold was assessed within the SCC and melanoma groups (Fig. 2a and b, respectively). A linear (Pearson) correlation test demonstrated a negative correlation between tumor size and pain threshold in all experimental cancer groups. However, the correlation was stronger with r = _0.726 in the melanoma group. (p < 0.0001) than in the SCC group with r = _0.351 (p = 0.0474). Treatment with ETAR antagonist, BQ123, significantly blocked OSCC pain whereas no affect was seen on melanomas that don’t secrete ET-1. | |
| Evidence Search |
(("Receptors, Endothelin"[Mesh] OR "Endothelin-1"[Mesh]) AND "Mouth Neoplasms"[Mesh]) AND "Pain"[Mesh]
...view in PubMed |
Comments on
The Evidence |
The design was a RCT. The groups were the same at the start and the groups were treated the same. There was a greater than 80% completion rate. There was adequate follow up and there does not appear to be any competing interests. |
| Applicability |
Currently only animal research is available. Future treatment regimens for cancer pain directed at ET-1 could be utilized through customized care (especially ET receptor A). |
| Specialty/Discipline |
(Oral Medicine/Pathology/Radiology) (Oral Surgery) |
| Keywords |
Animals, Carcinoma, Squamous cell/Pathology, Cell line, Tumor, Mice, Pain/drug therapy, Pain/etiology, Receptor, Endothelin A/antagonists & inhibitors
|
| ID# |
592 |
| Date of submission: |
04/01/2010 Revised: 12/06/2011 |
| E-mail |
adicks@livemail.uthscsa.edu |
| Author |
Jennifer Adicks |
| Co-author(s) |
|
| Co-author(s) e-mail |
|
| Faculty mentor/Co-author |
Cara Gonzales, PhD, DDS |
| Faculty mentor/Co-author e-mail |
gonzalesc5@uthscsa.edu |
Basic Science Rationale
(Mechanisms that may account for and/or explain the clinical question, i.e. is the answer to the clinical question consistent with basic biological, physical and/or behavioral science principles, laws and research?) |
post a rationale |
| None available | |
|
Comments and Evidence-Based Updates on the CAT
(FOR PRACTICING DENTISTS', FACULTY, RESIDENTS and/or STUDENTS COMMENTS ON PUBLISHED CATs) |
post a comment |
by Nicholas Cox, Jack Hua, Stacye Joyner (San Antonio, TX) on 01/07/2013
A PubMed search on the endothelin-1 concentration relation to pain threshold in a cancer pain mouse model produced two more recent publications: PubMed IDs 21972258
(Viet, 2012-research supported) 21782343
(Viet, 2011-review article). Both confirmed the previous CAT. | |
|
|
